GSRX Industries Inc. (GSRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 100.0% |
| 2019 | -22.46 Million USD | -32.83% |
| 2018 | -16.91 Million USD | 35.16% |
| 2017 | -26.08 Million USD | -43025.16% |
| 2016 | -60.48 Thousand USD | -1.96% |
| 2015 | -59.32 Thousand USD | -199.88% |
| 2014 | 59.38 Thousand USD | 0.73% |
| 2013 | 58.96 Thousand USD | 4.04% |
| 2012 | 56.67 Thousand USD | 197.44% |
| 2011 | -58.16 Thousand USD | -2.63% |
| 2010 | -56.67 Thousand USD | -1.31% |
| 2009 | -55.93 Thousand USD | -11.24% |
| 2008 | -50.28 Thousand USD | -307.4% |
| 2007 | 24.24 Thousand USD | 468.04% |
| 2006 | 4268.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 Q3 | -1.96 Million USD | -964.02% |
| 2020 Q2 | 227.48 Thousand USD | 73.3% |
| 2020 FY | - USD | 100.0% |
| 2020 Q1 | 131.26 Thousand USD | -97.73% |
| 2019 FY | -22.46 Million USD | -32.83% |
| 2019 Q4 | 5.77 Million USD | 132.72% |
| 2019 Q3 | -17.63 Million USD | -1808.69% |
| 2019 Q2 | -924.02 Thousand USD | 71.47% |
| 2019 Q1 | -3.23 Million USD | -15.43% |
| 2018 Q4 | -2.8 Million USD | -44.38% |
| 2018 Q2 | -1.5 Million USD | 82.33% |
| 2018 Q1 | -8.5 Million USD | 61.54% |
| 2018 FY | -16.91 Million USD | 35.16% |
| 2018 Q3 | -1.94 Million USD | -29.23% |
| 2017 Q3 | 659.44 Thousand USD | 120.0% |
| 2017 FY | -26.08 Million USD | -43025.16% |
| 2017 Q1 | -17.06 Thousand USD | -215.16% |
| 2017 Q4 | -22.12 Million USD | -3455.3% |
| 2017 Q2 | -3.29 Million USD | -19226.04% |
| 2016 FY | -60.48 Thousand USD | -1.96% |
| 2016 Q3 | -13.83 Thousand USD | 6.09% |
| 2016 Q4 | 14.81 Thousand USD | 207.08% |
| 2016 Q2 | -14.73 Thousand USD | 13.82% |
| 2016 Q1 | -17.09 Thousand USD | -216.63% |
| 2015 Q3 | -13.9 Thousand USD | -0.48% |
| 2015 FY | -59.32 Thousand USD | -199.88% |
| 2015 Q4 | 14.65 Thousand USD | 205.41% |
| 2015 Q2 | -13.84 Thousand USD | 18.17% |
| 2015 Q1 | -16.91 Thousand USD | -218.47% |
| 2014 FY | 59.38 Thousand USD | 0.73% |
| 2014 Q4 | 14.27 Thousand USD | 203.22% |
| 2014 Q1 | 16.73 Thousand USD | 21.7% |
| 2014 Q3 | -13.83 Thousand USD | 4.93% |
| 2014 Q2 | -14.54 Thousand USD | -186.92% |
| 2013 Q4 | 13.75 Thousand USD | -0.58% |
| 2013 Q3 | 13.83 Thousand USD | 201.3% |
| 2013 Q2 | -13.65 Thousand USD | -177.04% |
| 2013 Q1 | 17.72 Thousand USD | 36.94% |
| 2013 FY | 58.96 Thousand USD | 4.04% |
| 2012 Q3 | 15.53 Thousand USD | 36.55% |
| 2012 Q4 | 12.94 Thousand USD | -16.69% |
| 2012 Q1 | 16.82 Thousand USD | 213.5% |
| 2012 Q2 | 11.37 Thousand USD | -32.36% |
| 2012 FY | 56.67 Thousand USD | 197.44% |
| 2011 Q2 | 12.7 Thousand USD | -30.22% |
| 2011 Q3 | 12.42 Thousand USD | -2.27% |
| 2011 Q4 | -14.82 Thousand USD | -219.32% |
| 2011 FY | -58.16 Thousand USD | -2.63% |
| 2011 Q1 | 18.21 Thousand USD | 240.22% |
| 2010 Q1 | 18.63 Thousand USD | 251.82% |
| 2010 Q3 | 12.58 Thousand USD | 1.07% |
| 2010 Q4 | -12.98 Thousand USD | -203.19% |
| 2010 FY | -56.67 Thousand USD | -1.31% |
| 2010 Q2 | 12.45 Thousand USD | -33.17% |
| 2009 Q4 | -12.27 Thousand USD | -192.13% |
| 2009 Q2 | 12.9 Thousand USD | -25.96% |
| 2009 Q1 | 17.43 Thousand USD | 205.34% |
| 2009 FY | -55.93 Thousand USD | -11.24% |
| 2009 Q3 | 13.32 Thousand USD | 3.25% |
| 2008 Q4 | -16.54 Thousand USD | -222.97% |
| 2008 FY | -50.28 Thousand USD | -307.4% |
| 2008 Q1 | 11.48 Thousand USD | 76.16% |
| 2008 Q2 | 8796.00 USD | -23.41% |
| 2008 Q3 | 13.45 Thousand USD | 52.98% |
| 2007 Q2 | 6339.00 USD | 213.12% |
| 2007 FY | 24.24 Thousand USD | 468.04% |
| 2007 Q1 | -5604.00 USD | 0.0% |
| 2007 Q3 | 5782.00 USD | -8.79% |
| 2007 Q4 | 6519.00 USD | 12.75% |
| 2006 FY | 4268.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bright Green Corporation | -8.89 Million USD | 100.0% |
| BioQuest Corp. | -89.76 USD | 100.0% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 100.0% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 100.0% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | 100.0% |
| High Sierra Technologies, Inc. | -238.36 Thousand USD | 100.0% |
| Instadose Pharma Corp. | - USD | NaN% |